Join the club for FREE to access the whole archive and other member benefits.

Borja Ibañez

CNIC Clinical Research Director

Borja Ibáñez holds a degree in medicine from the Universidad Complutense de Madrid and PhD from the Universidad Autónoma de Madrid. He completed his clinical fellowship in cardiology at the Fundacion Jimenez Diaz Hospital in Madrid, during which he became interested in clinical research, working mainly with invasive imaging techniques for the study of the atherothrombotic disease. After completing his training in clinical cardiology, he made a training period of three years in basic research at Mount Sinai in New York. His doctoral thesis focused on the study of the ability of HDL-cholesterol to stabilize atheroma plaques and their assessment using non-invasive imaging tools. Since returning to Spain, he combines his scientific activity in the CNIC with clinical activity in the Fundación Jimenez Diaz University hospital. His passion is the study of myocardial diseases, with a clear translational vocation. His research ranges from the study of the mechanisms responsible for the development of myocardial diseases, to clinical trials to test therapies identified by his group in preclinical studies. His clinical activity consists mainly in coronary interventions of patients suffering an acute myocardial infarction. To perform this translational research, he uses noninvasive imaging technology, mainly magnetic resonance, also including the development of new imaging algorithms to improve the use both on research and clinical levels.

Visit website: https://www.cnic.es/en/borja-ibanez-cabeza

 borja-ibanez-9136b09a

 Borjaibanez1

See also: Company Centro Nacional de Investigaciones Cardiovasculares (CNIC) | Spanish National Center for Cardiovascular Research - International research center

Details last updated 21-Apr-2020

Borja Ibañez News

Fast progression of atherosclerosis seen in healthy people aged 40-50

Fast progression of atherosclerosis seen in healthy people aged 40-50

EurekAlert! - 06-Apr-2020

First of its kind to analyze the progression of the disease at frequent intervals